RecruitingNCT06367530

Trilateral Retinoblastoma: Incidence and Outcomes

Studying Hereditary retinoblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Amsterdam UMC, location VUmc
Principal Investigator
Marcus de Jong, MD PhD
Amsterdam UMC
Intervention
Incidence and survival of trilateral retinoblastoma and the differences globally(diagnostic_test)
Enrollment
4351 enrolled
Eligibility
All sexes
Timeline
2024 – 2029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06367530 on ClinicalTrials.gov

Other trials for Hereditary retinoblastoma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary retinoblastoma →

← Back to all trials